Process for Producing a Stable Low Concentration, Injectable Solution of Noradrenaline
US 10,251,848 Surrendered on reissueSurrendered on reissue Feb 21, 2023 · High confidence
20-year base term ends Feb 26, 2035
Surrendered on reissue Feb 21, 2023 · its term and maintenance fees continue in US RE49,422 and US RE49,443 and US RE49,555.
Feb 26, 2015
Feb 21, 2023
Apr 9, 2019
Feb 26, 2035
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Feb 26, 2015, when the earliest non-provisional application in its chain was filed (this one was filed Aug 13, 2016) | Feb 26, 2035 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 1 of 3 maintenance fees paid | no change | High confidence |
| Reissue | US RE49,422 and US RE49,443 and US RE49,555 issued Feb 21, 2023, and this patent's term continues in it (35 U.S.C. 251, 252) | surrendered Feb 21, 2023 | High confidence |
| Surrendered on reissue | The steps above, in order | Feb 21, 2023 | High confidence |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.